Country updates shared by Yong Hao Lim, HAEi’s Regional Patient Advocate, East Asia

Good news from East Asia: Clinical trial participation is increasing across the region. Japan, Korea, Hong Kong, and Singapore have all made progress, with Singapore participating as a trial site for the first time. China is also advancing, with plans for a trial on domestically produced plasma-derived treatments and the registration of a new trial evaluating a siRNA therapy for HAE. These developments mark an important step toward expanding treatment options for patients.

Treatment availability is also improving. Japan recently introduced a new prophylactic treatment option, and we remain hopeful that access will continue to expand throughout the region.